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BACKGROUND AND PURPOSE
A major obstacle to islet cell transplantation is the early loss of transplanted islets resulting from the instant blood-mediated in-
ﬂammation reaction (IBMIR). The activation of complement pathways plays a central role in IBMIR. The aim of this study was to
test the inhibitory effect of “painting” human islets with APT070, a membrane-localizing C3 convertase inhibitor, on inﬂamma-
tion evoked by exposure to human serum in vitro and by transplantation in vivo in a humanized diabetic mouse model.
EXPERIMENTAL APPROACH
In vitro, human islets pre-incubated with APT070 were exposed to allogeneic whole blood. In vivo, similarly treated islets were
transplanted underneath the kidney capsule of streptozotocin-induced diabetic NOD-SCID IL2rγ/ mice that had been
reconstituted with human CD34+ stem cells. Complement activation and islet hormone content were assayed using enzyme-
linked immunosorbent assays. Supernatants and sera were assayed for cytokines using cytometric beads array. Morphology of the
islets incubated with human serum in vitro and in graft-bearing kidney were evaluated using immunoﬂuorescence staining.
KEY RESULTS
Pre-incubation with APT070 decreased C-peptide release and iC3b production in vitro, with diminished deposition of C4d and
C5b-9 in islets embedded in blood clots. In vivo, the APT070-treated islets maintained intact structure and showed less inﬁltration
of inﬂammatory cells than untreated islets. The pretreatments also signiﬁcantly reduced pro-inﬂammatory cytokines in superna-
tants and sera.
CONCLUSIONS AND IMPLICATIONS
Pre-treatment of islets with APT070 could reduce intra-islet inﬂammation with accompanying preservation of insulin secretion by
beta cells. APT070 could be as a potential therapeutic tool in islet transplantation.
Abbreviations
CR1, complement receptor 1; hu-NSG, humanized NSG; IBMIR, instant blood-mediated inﬂammation reaction; iC3b,
inactivated C3b; IEQs, islet equivalents; LDH, lactate dehydrogenase; NSG, non-obese diabetic/severe combined
immunodeﬁciency/interleukin-2 receptor γ-chain knockout; sCR1, soluble complement receptor 1 (sCR1); UCB, umbilical
cord blood
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Introduction
Type 1 diabetes (T1D) is characterized by permanent destruc-
tion of insulin-producing beta cells in the pancreatic islets.
Transplantation of islets of Langerhans via intra-portal injec-
tion is a promising treatment procedure for patients with se-
vere T1D (Robertson, 2010). However, despite recent
progress, the procedure is associated with massive tissue loss
caused by an inﬂammatory reaction, referred to as the instant
blood-mediated inﬂammatory reaction (IBMIR) (Nilsson
et al., 2011). It is believed that complement attack is a major
cause of the damage to the islets that occurs during the IBMIR
(Tjernberg et al., 2008) and the reaction involves rapid activa-
tion of the coagulation and complement system, activation
and binding of platelets to the islet surface, and inﬁltration
of leukocytes into the islets (Nilsson et al., 2011). The comple-
ment cascade therefore makes a logical therapeutic target for
the reduction of graft rejection (Farrar and Sacks, 2014).
The central step in the complement cascade is the cleav-
age of C3 to C3b by C3 convertase. This leads ultimately to
the assembly of the membrane attack complex (MAC) and
the release of soluble C3a and C5a, which in turn activate
and recruit inﬂammatory cells (Sacks et al., 2009). Once C3
is deposited covalently as C3b on a membrane, it has two
fates. The ﬁrst is an ampliﬁcation step, in which more C3 is
cleaved and bound to the membrane. This process involves
a further complement protein, factor B. When factor B binds
to C3b, it is activated by the complement enzyme factor D
and forms the C3 convertase enzyme C3bBb. This enzyme
cleaves more C3, causing manymore C3b molecules to be de-
posited on the membrane. The second possible fate of bound
C3b is catabolism to iC3b (inactivated C3b) and C3dg, creat-
ing adhesive contact with corresponding receptors on
leucocytes through the complement receptors, CR1-4, partic-
ularly CR3 and CRIg (Walport, 2001a; Walport, 2001b). This
step is mediated by regulators that inactivate complement
binding to C3b thus promoting its removal and degradation
from the enzyme complexes that convert C3 and C5 into
their active forms. The regulators exist as membrane bound
(e.g. CD35, CD46 and CD55) and soluble (e.g. Factor H) pro-
teins. APT070, also known as Mirococept, is a modiﬁed frag-
ment of the complement receptor 1 (CR1, CD35)
(Mossakowska et al., 1999; Smith, 2002). It consists of the ﬁrst
3 consensus domains of the human CR1 and a membrane-
interacting synthetic peptide, which mediates binding to
phospholipids on the cell surface and therefore protects the
cell against complement activation (Smith and Smith, 2001;
Smith, 2002). APT070 showed inhibition of complement
and neutrophil activation during cardiopulmonary bypass
in man in vitro (De Silva et al., 2006), and of the inﬂammatory
responses that follow intestinal (Souza et al., 2005) and renal
(Patel et al., 2006) ischaemia and reperfusion injury in rat
models. These studies have prompted clinical investigation
of the utility of APT070 in man for ischaemia-reperfusion in-
jury during renal transplantation (Smith, 2007). These prop-
erties suggested the possible use of APT070 in protecting
human islet transplantation.
The development ofmice that are ‘humanised’ by engraft-
ment of human tissues, haematopoietic stem cells or
peripheral-blood mononuclear cells (PBMC), provides an op-
portunity to study human biological processes in vivo that
would otherwise not be possible (Shultz et al., 2007). We have
recently described human islet allograft rejection in the
CD34+ stem cell-reconstituted humanized mouse model
(Xiao et al., 2014). Although islets were placed underneath
the kidney capsule, rejection was associated with C3b deposi-
tion and we suggested that complement may be involved in
the recruitment and activation of innate inﬂammatory cells.
We therefore hypothesised that inhibition of complement ac-
tivation might enhance islet survival. The present study
aimed to investigate whether APT070 could protect human
islets from complement-mediated destruction in vitro, and at-
tenuate the immune response to human islet allograft in vivo
in the humanized mouse model (Xiao et al., 2014).
Methods
Preparation of human islets
The procurement and use of all human tissues were with
signed informed consent, in accordance with the Declaration
of Helsinki and approval from the Institutional Review Board
of King's College London. Human islets were obtained from
King's Cell Isolation Unit, London, UK. Freshly isolated hu-
man islets were incubated with serial dilutions of
membrane-localizing complement regulator APT070 [0.4–
1.6 μM; 3000–4000 human islet equivalents (IEQ) mL  1],
or its control molecule APT154 at the equivalent molar con-
centration, in CMRL 1066 culture medium (Invitrogen) con-
taining 2.5% human albumin at 37 °C in an atmosphere of
95% air 5% CO2 for one hour (Figure 1). The recombinant
non-tailed CR1 fragment APT154 possesses chemical and
complement inhibitory properties identical to those of
APT070, but is untagged and therefore does not contain the
membrane-binding moiety (Banz et al., 2007). This control
molecule was prepared using the cloning and expression
strategy as previously described (Dodd et al., 1995;
TARGETS
GPCRs
C3a receptor
LIGANDS
C3a, complement component C3a
Carbachol
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Mossakowska et al., 1999; Smith, 2002). To detect the
bound APT070, the treated islets were incubated with a
rabbit polyclonal antibody raised against recombinant SCRs
(1–3) of CR1 (APT3677, 100 μg mL  1) (Dodd et al., 1995).
Antibody APT3677 was a product of Adprotech Ltd.
(Saffron Walden, UK) and is available for research purposes
from King's College London (Dr. Richard A Smith). After
washing, tetramethylrhodamine isothiocyanante (TRITC)-
conjugated goat anti-rabbit IgG was applied for one hour
at room temperature. Images were acquired using a Cooled
Mono14 Bit camera (Q IMAGING, Canada) and Micro-
Manager 1.3 software (University of California, USA).
In vitro viability and functional assessment of
APT070-treated islets
APT070-treated islet viability was assessed by a ﬂuorometric vi-
ability assay, using ﬂuorescein diacetate and propidium iodide
(Sigma, Dorset, UK) (Hansen et al., 1989; London et al., 1989),
and kits of the CellTiter-Glo Luminescent Cell Viability Assay
(Promega, Southampton, UK) and lactate dehydrogenase
(LDH) assay, according to the manufacturers' instruction. For
measuring the dynamics of insulin release, islets were
transferred into chambers (50 islets per chamber) of a
temperature-controlled multichannel perifusion system as
previously described (Jones et al., 1989). The loaded islets were
subsequently perifused (0.5 ml min1) with 2 mM glucose for
10 min and 20 mM glucose for 20 min in Gey's balanced salt
solution [0.05% (w/v) BSA, 2 mM CaCl2, 111 mM NaCl, 5 mM
KCl, 27 mM NaHCO3, 1 mM MgCl2, 0.22 mM KH2PO4 and
0.28 mM MgSO4], followed by an additional perifusion of
500 μM carbachol for 18 min. Sampling was performed at
2 min intervals. In another experiment, the extracts of islet
pellets were prepared using acid-ethanol. Insulin content was
assessed by radioimmunoassay (RIA) using in-house assay, as
described previously (Jones et al., 1988).
In vitro model of allogeneic blood-islet
combinations
Approximately 2500 IEQs APT070-treated islets with a purity
of 60–80% were re-suspended in 1 ml of culture medium and
placed in 35-mm polystyrene petri dishes (BD). One millilitre
of freshly drawn humanwhole blood, ABO blood group typed
for compatibility with the islet donor, was added and incu-
bated in 37 °C for 30 min. Supernatants were then collected,
with the addition of EDTA (10 mM ﬁnal concentration) to
prevent further complement activation (Mollnes et al.,
2002). These were immediately stored with protein inhibitor
cocktail (Sigma) at -80C for future use.
Humanized mouse model with APT070-treated
islet transplantation
Reconstitution ofmice with human stem cells. All animal care and
experimental procedures complied with the institutional
guidelines and the Home Ofﬁce Animals Scientiﬁc Procedures
Act (1986) (UK) and were approved by the Ethical Review
Process Committee, King's College London, UK (Project no:
70/7302). These studies comply with the recommendations on
experimental design and analysis in pharmacology (Curtis
et al., 2015) and the animal studies follow the ARRIVE
guidelines (McGrath & Lilley, 2015; McGrath et al., 2015). All
animal studies were randomized and observations were made
without knowledge of the treatments.
Non-obese diabetic/severe combined immunodeﬁciency/
interleukin-2 receptor γ-chain knockout (NOD/SCID/IL2Rγ/
, referred to here as NSG; The Jackson Laboratory) mice were
bred and maintained in the Biological Services Unit of
King's College London under speciﬁc pathogen-free condi-
tions. Umbilical cord blood (UCB) was obtained from full-
term normal deliveries. UCB-derived CD34+ stem cells were
isolated as described by Xiao et al. (2014). Brieﬂy, mononu-
clear cells were isolated by Ficoll-Paque (GE Healthcare,
Figure 1
Schematic description of the in vitro model mimicking IBMIR, and in vivo model of humanized NSG mice.
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Hatﬁeld, UK) gradient separation and enriched for CD34+
cells using positive isolation kit according to the manufacturer's
instructions (Miltenyi Biotech, Surrey, UK).Mice (6–8weeks old)
were gamma-irradiated (240 cGy) and then intravenously
injected with 2 x 105 CD34+ stem cells (referred to as
hu-NSG mice).
Flow cytometric analysis of human haematopoietic engraftment. Tail
bleeding was performed in hu-NSG mice 12–16 weeks after
injection of CD34+ cells. Blood cells were prepared for ﬂow
cytometry as previously described (Xiao et al., 2014).
Fluorochrome-coupled antibodies speciﬁc for human CD45
were used for detection of human leukocytes. Flow cytometric
data were acquired using a FACS Calibur (BD Biosciences, San
Jose, CA, USA) and analysed using FlowJo 7.5 software
(TreeStar Inc.).
Islet transplantation into diabetic ‘humanized' NSG mice. NSG
and hu-NSG mice were rendered diabetic (blood glucose
level ≥ 20 mM) by a single i.p. injection of streptozotocin
(180 mg kg1) and transplanted with human APT070-
treated islets (IEQs, 3000–4000) under the left kidney
capsule as previously published (Xiao et al., 2014). During
the surgery, the recipient animals were anaesthetized using
3% isoﬂurane in a stream of 100% O2 (2 l min1), and
were maintained using 1.5–2.0% isoﬂurane in a stream of
100% O2 (2 l min1). The animals were placed on a heat
pad to keep body temperature at 37 °C throughout the
procedure. Blood glucose concentration of recipient mice
was monitored every 24 hours at the ﬁrst week and twice a
week thereafter using a blood glucose sensor (Abbott
Diabetes Care Ltd., Witney, Oxon, UK). Reversal of
hyperglycaemia was deﬁned as non-fasting blood glucose
concentration ≤ 13.8 mM (King et al., 2008). NSG mice with
successful transplants were subjected to unilateral left
nephrectomy to evaluate a return to hyperglycemic state.
For islet-transplanted diabetic hu-NSG mice, sera were
collected by tail sampling at day 5 and day 9 after
transplantation, and kept at 80 °C prior to use for further
test. The animals were sedated with CO2 and killed by
decapitation at the end of experiments.
Enzyme-linked immunosorbent assay (ELISA) for human insulin,
C-peptide and iC3b. Supernatant insulin and C-peptide
concentrations were assayed using ELISA kits (Millipore,
Watford, UK). ELISA kit for human iC3b (Pathway
Diagnostics Ltd., Surrey, UK) was used to determine levels of
soluble complement activation product iC3b in supernatant
and sera, according to the manufacturer's instructions. All
samples were tested in triplicate in the assays.
Cytokine detection (beads array)
Human cytokines in supernatants and sera were assayed
using a human Th1/Th2 11plex kit (eBiosciences) according
to the manufacturer's protocol. Data acquisition was per-
formed on a FACS Calibur (BD Biosciences) and analysed
using The FlowCytomix Pro 3.0 Software from eBioscience
(Xiao et al., 2014).
Histology analysis
Deposition of activated complements was examined in the
islets embedded in blood clots after 60 min incubation
with blood, and the harvested graft-bearing kidney at day
5 after transplantation. The samples were ﬁxed in 10%
buffered formalin, and embedded in parafﬁn. Sections
(5 μm) were processed with double immunoﬂuorescence
staining. After antigen retrieval by microwaving for
5 min in 0.01 M citrate buffer (pH 6.0), sections were
blocked with 10% goat normal serum for 30 min and then
incubated overnight at 4 °C with primary antibodies: rab-
bit anti-human insulin (1:300; Bioss, polyclonal), mouse
anti-human C4d (1:25; Abcam, clone LP69), mouse anti-
human C5b-9 (1:100; Abcam, clone aE11), mouse anti-
human CD11b (1:50; eBiosciences, clone ICRF44) and
mouse anti-human CD66b (1:50; BioLegend, clone
G10F5). Secondary antibodies FITC-conjugated goat anti-
mouse IgG and TRITC-conjugated goat anti-rabbit IgG
(both Sigma) were applied for 2 hours at room temperature
(Xiao et al., 2014). Negative controls with non-speciﬁc IgG
were processed in parallel. Images were acquired using a
Nikon Eclipse Ti-E Inverted microscopy with 4 x GaAsP
Detectors and A1R Si Confocal system with a 60x objective
lens and analysed by NIS-Elements Advanced Research
imaging analysis software (Nikon, Surrey, UK). Where the
inﬁltrated cells were quantiﬁed, each sample from an indi-
vidual animal (n = 5 animals) was assessed and analysed
by using ImageJ software. The deposition of complement
was quantiﬁed by measuring the mean ﬂuorescence inten-
sity (MFI) in the region of interest area.
Data analysis
Data are presented as means ± SD. All statistical analysis was
performed using the two-tailed Student's t-test or two-way
ANOVA analysis, followed by Bonferroni post hoc tests. P
values <0.05 were considered signiﬁcant.
Materials
APT070 and APT 154 were supplied by Adprotech Ltd.
(Saffron Walden, UK); carbachol and streptozotocinwere sup-
plied by Sigma (Dorset, UK).
Results
Human islets display physiological responses
after treatment with APT070
To ensure that APT070-treated islets were viable and physi-
cally identical to the freshly prepared islet, we examined the
effects of APT070 on the viability of human islets. Human is-
lets were incubated in vitro for one hour in culture medium
alone (control group) or with APT070 and its control mole-
cule APT154 (Figure 1). The data demonstrate that APT070,
but not APT154 bound to the islet (Figure 2A). Dose-titration
of APT070 from 0.4 to 1.6 μM (25–100 μg mL  1) showed
that the lowest dose (0.4 μM) treatment had no effect on islet
viability in the ﬂuorescein diacetate and propidium iodide
staining (Supplementary Figure S1). This was conﬁrmed by
cell viability assay based on quantitation of the APT present
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(Figure 2B) and the measurement of intracellular content of
insulin (Figure 2C). Therefore APT070 was used at a concen-
tration of 0.4 μM (25 μg mL  1) in further studies. It should
be noted that a concentration of 10 μg mL  1 of APT070
has been used in perfusion experiments in human renal
transplantation without apparent adverse effects (Smith
et al., 2007).
To evaluate islet function after incubation with APT070,
measurements of the rate and pattern of insulin secretion
from perifused islets (Figure 2D) conﬁrmed that APT070 pre-
treatment did not inhibit insulin secretory responses to glu-
cose, nor to the receptor-mediated agonist, carbachol.
Expressing the cumulative total insulin secretion during the
perifusion as area under the curve (AUC) showed that
Figure 2
Assessment of islet viability and secretion function. (A) Binding of APT070 (0.4 μM) to human islets one hour after incubation. Positive bind-
ing is shown in red. Ampliﬁer power: × 60. (B) Islet viability assay. Luminescent outputs, which correlated with islet cell numbers, were mea-
sured in APT070 treated and control islets. Values represent the mean ± SD, n = 6 (wells of 96-well plate). (C) Intracellular insulin content in
APT070-treated and control islets. The data are expressed as means ± SD, n = 6. (D, E) The dynamics of insulin release. Data are shown as
means ± SD, n = 8 perifusion channels. RLU: relative luminescence units. AUC: area under curve. Control islets received no treatment. NS: no
signiﬁcant difference.
Complement inhibitor protected human islet allograft BJP
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APT070 pre-treatment had no signiﬁcant effects on insulin
secretion (Figure 2E), conﬁrming that the β-cells remained
functionally viable after treatment.
Pre-incubation of human islet with APT070
prevents the production of activated
complement in vitro and in vivo
To test whether APT070 has an inhibitory effect on comple-
ment activation, islets were exposed to whole blood for 30mi-
nutes. The level of iC3b was signiﬁcantly decreased in the
supernatant of APT070 treated-islets, compared with control
groups (n = 6 for each group) (Figure 3A).
To further assess the in vitro inhibitory effects of APT070
on complement activation, C4d deposition, as an indicator
of complement activation, and C5b-9, which may cause
cell lysis in the blood-exposed islets, were examined. Pre-
treatment of islets with APT070 almost abolished deposi-
tion of both C4d and C5b-9 in the islet exposed to blood
for 60 minutes (Figure 3B, C).
To evaluate the in vivo effects of APT070 on human allo-
graft, humanized mice were generated (hu-NSG mice) as pre-
viously described (Xiao et al., 2014). Immunodeﬁcient mice
(NSG) of 4–6 weeks old were engrafted with UCB-derived
CD34+ stem cells and, after 16 weeks, a signiﬁcant percentage
of human CD45+ cells was detectable in the blood of these
mice (Supplementary Figure 2). APT070-treated islets were
transplanted under the kidney capsule of hu-NSG mice.
Although the kidney capsule is not a site where classical
IBMIR occurs, deposition of human C3 on human islets im-
planted beneath the kidney capsule of hu-NSG mice, associ-
ated with circulating human C3, has previously been shown
(Xiao et al., 2014), therefore it is appropriate to assess the ef-
fect of APT070 on these parameters. The level of human
iC3b was found to be decreased in the sera of mice receiving
APT070 treated-islet at day 5 after transplantation, compared
with controls (Figure 4A). Furthermore, there was very little
deposition of C4d and C5b-9 in the islet allografts in the
APT070 treated group. In contrast, allografts from hu-NSG
mice that had received untreated-islets exhibited an abun-
dant staining for C4d and C5b-9 (Figure 4B). There was a sig-
niﬁcant difference between the two groups (Figure 4C).
APT070 reduces human islet destruction in
human blood in vitro and in islet allografts in
humanized NSG mice
To evaluate the damage in islets exposed to blood in vitro, the
release of C-peptide and of LDH were assessed as indicators of
beta cell damage. Measurements of C-peptide and LDH in
Figure 3
iC3b in supernatants and deposition of C4d and C5b-9 in blood clot-embedded islets. (A) Supernatants were collected 30 min after islet exposure
to allogeneic whole blood and were assayed for iC3b level by ELISA, n = 6. (B) Freshly isolated islets were pre-incubated with APT070 (0.4 μM) or
with culture medium alone (control) for one hour, following by exposed to allogeneic whole blood for one hour. Blood clot-embedded islets were
stained with antibodies speciﬁc for insulin and C4d or C5b-9 molecules. Images are representative from 6 sections in each group. (C) Quantitative
analysis of blood-embedded islet immunostaining. Staining for C4d and C5b-9 is shown in green. Nuclei were stained with DAPI (blue). Yellow
indicates co-localization of insulin and C4d/C5b-9. Data are expressed as means ± SD. *: P< 0.05; **: P< 0.01; signiﬁcantly different as indicated.
MFI: mean ﬂuorescence intensity.
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supernatants 30 min after incubation of untreated islets
with human blood showed signiﬁcant increases, consistent
with islet cell damage (Figure 5). However, the release of C-
peptide and LDH was completely inhibited in the APT070-
treated group, demonstrating protection from blood-
mediated islet cell damage (Figure 5).
Activated complement proteins C3a and C5a act as
chemoattractants to recruit human leukocytes (Li and
Zhou, 2013). To evaluate the inhibitory effect of
APT070 on the production of these molecules, inﬁltra-
tion of human CD45+ cells, macrophages (CD11b+)
and neutrophils (CD66b+) into graft-bearing kidneys,
5 days after transplantation was examined. APT070-
treated islets displayed intact structure with decreased
inﬁltration of these inﬂammatory cells, compared with
controls (Figure 6).
Figure 4
Serum iC3b levels (A) and deposition of C4d and C5b-9 in islet graft bearing kidney. Sera (A) and islet graft-bearing kidneys (B) were collected
from humanized NSG mice 5 days after islet transplantation. (C) Quantiﬁcation of the deposition of C4d and C5b-9 in the graft-bearing kidney.
Islets were pre-incubated with APT070 for one hour before surgery. Staining for C4d and C5b-9 are shown in green. Nuclei were stained with DAPI
(blue). n = 5 mice for each group. Data are expressed as means ± SD. Control islets were incubated with culture medium alone. **: P < 0.01; sig-
niﬁcantly different as indicated. MFI: mean ﬂuorescence intensity.
Figure 5
C-peptide and LDH levels in supernatant from co-culture of human islet and allogeneic whole blood. The supernatants were sampled 30 min after
exposure of human islets to allogeneic whole blood. Data are means ± SD of 6 Eppendorf tubes from two independent experiments. **: P < 0.01;
signiﬁcantly different as indicated. NS: no signiﬁcant difference. Control islets had no treatment.
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Pre-incubation of islets with APT070
suppresses cytokine production in vitro and at
early stages in vivo
To further demonstrate the protective effect of APT070 on
islet graft, human cytokine proﬁles were evaluated both
in vitro and in vivo. A bead based Analyte Detection System
was used for quantitative detection of human IFN-γ, IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α and TNF-β in the
supernatants taken from the incubation of islets with blood,
and in sera from islet-transplanted humanized mice. Analysis
revealed that treatment with APT070 signiﬁcantly reduced
levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-10, TNF-α and
TNF-β, with no effect on IL-12, IL-8 and IL-6 (n = 6) (Figure 7A),
following 30 minutes incubation.
In vivo, serum levels of human IFN-γ and IL-2 were signif-
icantly reduced in humanized mice 5 days after APT070
treated-islet grafting, compared with untreated-islet controls
(n = 5 animals for each group) (Figure 7B), although IFN-γ
values were the same after 9 days. IL-1β, IL-6, IL-8, IL-10 and
TNF-α were undetectable (Figure 7C).
Pre-treatment of islets with APT070 induces
earlier reversal of hyperglycaemia in vivo
To correlate in vitro insulin secretion measurements with the
ability of islets to restore normoglycemia in vivo, APT070-treated
islets were transplanted under the kidney capsule of diabetic
hu-NSG mice and NSG mice that did not receive CD34+ cells.
Hyperglycaemia in both diabetic NSG (Figure 8A) and
hu-NSG mice (Figure 8B) was reversed earlier with APT070
treated islets, compared with the control islets, although
normoglycaemia was not attained in hu-NSG mice by the
end of the experiment (5 days) (Xiao et al., 2014). To deter-
mine the function of the transplant, the NSG mice
underwent unilateral left nephrectomy at 60 days after
transplantation. The data showed that a hyperglycemic
state was restored within 24–48 hours after nephrectomy
(Supplementary Figure 3).
Discussion
In this study, it was found that a membrane-localizing C3
convertase inhibitor (APT070) inhibited complement activa-
tion in vitro in a model mimicking IBMIR, and in vivo in hu-
manized mice transplanted with human islets. The data
demonstrated that APT070 protects human islet allografts
from complement-mediated damage through inhibition of
inﬁltrates into grafts and regulation of cytokine production.
IBMIR is one of the main challenges faced by clinical islet
transplantation and results in signiﬁcant destruction of islets
Figure 6
Inﬁltration of human leukocytes into human islet allografts from humanized NSG mice. Human islet grafts were harvested 5 days after transplan-
tation and were ﬁxed, embedded and sectioned. Samples were stained with H&E or with antibodies speciﬁc for human antigen: insulin (red),
CD45 (green), CD66b (green), and CD11b (green). Nuclei were stained with DAPI (blue). HE staining shows massive inﬁltration of leukocytes
in control grafts (A, H&E) compared to APT070 treated grafts (B, H&E). Images are representatives for control group (A) and APT070-treated
group (B). (C) Quantiﬁcation of inﬁltration of CD66b and CD11b positive cells. n = 5 slides for each group. Data were represented as means ±
SD of cell number in the ﬁeld in ampliﬁer power × 60. Cell numbers were counted in 3–5 ﬁelds in each slide and average was determined.
H&E: haematoxylin and eosin staining. C: kidney capsule. Insets in the H&E staining images show enlarged area indicated by a black arrow.
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(Bennet et al., 2000a; van der Windt et al., 2007). IBMIR is
believed to be a non-speciﬁc inﬂammatory response related
to the transplantation of islets directly to the blood mi-
croenvironment of the portal vein. It is probable that
implanted islets express tissue factor (CD142) that activates
the coagulation system. As a result, complement is activated
and the islets are destroyed by innate factors. In the present
study, the pathophysiological events triggered during direct
exposure of human islets to an allogenic blood in vitro,
mimicking clinical transplantation of human islets into
the portal vein, have been characterised. Notably, the non-
physiological release of C-peptide, which indicates massive
beta cell death, was observed in vitro (Figure 5). This is consis-
tent with the in vivo reports of auto-, allo-, and xeno-islet
transplantation (Moberg et al., 2002; Mollnes et al., 2002).
Thus, incubation of human islets with allogenic blood has
been proved to be a valuable model to investigate the events,
as previously shown in a similar approach by van der Windt
et al. (2012).
Incubation with anti-coagulation agents leads to the sur-
face modiﬁcation of islets, which can inhibit IBMIR (Chen
et al., 2011; Teramura and Iwata, 2011). Different compounds
targeting the complement system have been tested in vitro
and/or in vivo to improve early islet survival in experimental
models, such as the C5a inhibitory peptide (Tokodai et al.,
2010) and soluble complement receptor 1 (TP10) (Bennet
et al., 2000b; Lundgren et al., 2001). Although a high-dose,
systemic i.v. infusion of soluble complement receptor 1
(sCR1) (40 mg kg1) has been shown to improve
hyperacute xenograft rejection (Bennet, et al., 2000b), the
immobilization of sCR1 on islets was more effective than
systemic infusion (Luan et al., 2011). Like the immobilized
sCR1, APT070 is a membrane-bound protein, which inhibits
complement activation at appropriate sites. When freshly
isolated human islets were pretreated with APT070
(25 μg mL1) for one hour, there was no a deleterious effect
on islet secretory function (Figure 2). Glucose-induced insu-
lin secretion requires a depolarisation-dependent inﬂux of
extracellular Ca2+ via voltage-dependent calcium channels
Figure 7
Supernatant and serum levels of cytokines. Supernatants were
collected 30 min after exposure of islet to allogeneic whole blood
(A). Sera were obtained from islet-transplanted humanized NSG
mice 5 (B) and 9 (C) days after transplantation. For supernatants,
n = 6; for sera, n = 5 animals for each group. Values are mean ± SD.
*P< 0.05. ** P< 0.01; signiﬁcantly different as indicated. NS: no sig-
niﬁcant difference. Control islets had no treatment.
Figure 8
The plasma glucose level in the APT070-treated and untreated
human islet transferred into NSG (A) and hu-NSG (B) mice rendered
diabetic with streptozotocin. Tail blood was assessed for glucose
after islet transplantation. n = 5 animals for each group. Data are
expressed as means ± SD. *P < 0.05. **P < 0.01; signiﬁcantly
different as indicated. STZ: streptozotocin. Control islets had no
treatment.
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(VDCC) so the maintenance of normal secretory responses to
glucose demonstrates that using the membrane bound
APT070 did not adversely affect the beta cell membrane po-
tential, nor the normal operation of VDCC. Similarly, the
ability of pre-treated islet to respond to the muscarinic
cholineric agonist carbachol conﬁrms that coating the islets
with APT70 did not interfere with receptor expression or in-
tracellular signalling pathways.
The present data also show that the pretreatment with
APT070 resulted in a signiﬁcant decrease in the release of
C-peptide and LDH from islets after incubation with
human blood. Consistent with this, a peak serum level
of C-peptide can be associated with early islet cell death
and/or islet destruction in patients with allo-trans-
plantation (Moberg et al., 2002). The strategy of ‘painting’
APT070 on islets was also effective in preventing com-
plement activation, as shown by the decreased produc-
tion of soluble iC3b in vitro (Figure 3). Analysis of islet
morphology revealed damaged islets embedded in blood
clots with C4d and C5b-9 deposited on the islet surface
in untreated islets, but not in the APT070 pre-treated
group. This ﬁnding reﬂects clinical studies that suggest
that C4d-positive interacinar capillaries correlate with
donor-speciﬁc antibody-mediated rejection in pancreas
allografts (Torrealba et al., 2008). Similar results have
been obtained showing that APT070 completely
prevented complement membrane attack complex for-
mation at the nerve terminals in Miller Fisher
Syndrome (Halstead et al., 2005).
Expression of inﬂammatory mediators in isolated islets
with immune modulating capacity could markedly inﬂuence
the outcome of clinical islet transplantation (Johansson et al.,
2003). Use of APT070 has the potential to attenuate
hyperinﬂammatory responses through reduction of local
damage caused by the membrane attack complex (MAC) as
well as by reduction of neutrophil activation directly through
inhibition of C3a/C5a release and indirectly through inhibi-
tion of the complement-mediated release of cytokines (Souza
et al., 2005). Our data showed that inhibition of the comple-
ment cascade by APT070 resulted in signiﬁcantly decreased
concentration of a number of pro-inﬂammatory cytokines,
including IFN-γ, IL-2, IL-10, IL-4, IL-5, IL-1β, TNF-α and
TNF-β (Figure 7), consistent with a protective effect of
APT070 against cytokine-mediated damage to islet cells in
the immediate post-transplantation period. IL-10 is a major
protective endogenous cytokine in an islet xenograft rejec-
tion model (Yi et al., 2012) and during intestinal reperfusion
injury in rats (Souza et al., 2003). Thus, it is clear that
APT070 inhibits complement activation and islet damage
by a mechanism other than by IL-10 production. Interest-
ingly, complement inhibition did not have an effect on IL-8,
which is the most relevant pro-inﬂammatory cytokine found
both in transplanted patients and in the murine counterpart
after experimental islet transplant (Citro et al., 2013). An ex-
planation for this effect may lie in the time of sampling. Poly-
morphonuclear leukocytes (PMNs) and monocytes are the
dominant cell types inﬁltrating the islet and producing cyto-
kines in vitro, appearing in large numbers, 2 hours after incu-
bation with ABO-compatible blood (Moberg et al., 2005),
which is much later than our sampling time at 30 min.
Equally beneﬁcially, as IL-6 protects pancreatic islet beta cells
from pro-inﬂammatory cytokine-induced cell death and
functional impairment in vitro and in vivo (Choi et al.,
2004), it is remarkable that APT070 had no effect on the pro-
duction of IL-6.
Immunodeﬁcient mice that are engrafted with human
functional cells (termed as humanized mice) are ideal pre-
clinical models to investigate human immune responses in
an in vivo setting (Brehm, et al., 2010a; Shultz et al., 2007;
King et al., 2008). Non-obese diabetic/severe combined im-
munodeﬁcient mice harbouring a complete null mutation
of IL-2 receptor γ chain, NOD/SCID IL2r γnull (NSG), are
characterised by impairment in murine T-, B- and NK-cell
development and function(Cao et al., 1995; DiSanto
et al., 1995; Ohbo et al., 1996), and can efﬁciently support
the development of a functional human hemato-
lymphopoiesis (Brehm, et al., 2010b; Ishikawa et al.,
2005; Watanabe et al., 2009). Using the diabetic human-
ized NSG mouse model (Xiao et al., 2014), we found
that inhibition of the complement cascade by APT070
signiﬁcantly decreased concentration of at least two
pro-inﬂammatory cytokines, IL-2 and IFN-γ (Figure 7).
Whether APT070 had the same effects on cytokine proﬁle
in vivo are not known, because some human cytokines
are undetectable in the humanized mice system (Xiao
et al., 2014). Nevertheless, in support of this concept,
there was, at an early stage in the APT070-treated animals,
a marked inhibition of other cytokines, including TNF-α,
TNF-b and IL-6 (Souza et al., 2005). The mechanisms un-
derlying the inhibitory effects of APT070 on cytokines
need to be further investigated. There are a number of lim-
itations that prevent full use of our model system. In NSG
mice, the human T cells are restricted to mouse major his-
tocompatibility complex (MHC) and fail to interact pro-
ductively with human antigen presenting cell within the
host, leading to lack of class switching and immunoglobu-
lin G (IgG) antibody production (Watanabe et al., 2009;
Xiao et al., 2014). The generation of memory T cells in
the model can also be problematic (Brehm et al., 2013).
This insufﬁcient development of antigen-speciﬁc immu-
nity might explain why some of human cytokines could
not be identiﬁed in our model system. To overcome these
limitations, investigators have developed HLA-transgenic
NSG mice (Shultz et al., 2010; Covassin et al., 2011;
Serra-Hassoun et al., 2014).
Using the hu-NSG mice, we have recently shown a close
relationship between complement C3d deposition and the
damage of human islet allografts (Xiao et al., 2014). The com-
plement detected in this model system was human. The re-
sults suggested that complement might be involved in the
destruction of islets even in the context of being placed under
the kidney capsule, a site at which classical IBMIR does not
occur (Xiao et al., 2014). Now, using the same mouse model
(Supplementary Figure S2), we have found that ATP070 mark-
edly decreased complement deposition and inﬁltration of in-
ﬂammatory cells at the early stage (Figure 4, 6), consistent
with the in vitro data presented here. Consistently, APT070
treatment decreased serum levels of iC3b. These data indicate
an inhibitory effect of APT070 on local production of comple-
ment. Indeed, within the graft, local production of comple-
ment contributes to non-speciﬁc inﬂammation and
parenchymal destruction (Brown et al., 2006). It has been
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known for several years that innate immune cells, including
macrophages and dendritic cells, can express and secrete a va-
riety of complement components (Sacks et al., 2009). These
appear to be sufﬁcient for the cleavage of C3 in the local in-
ﬂammatory environment (Zhou et al., 2006; Peng et al.,
2008). The data also suggested that pre-incubation of human
islet with APT070 may have partly affected reversal of
hyperglycaemia in vivo in humanized NSG mice (Figure 8).
Complete restoration of normoglycemia in APT070-treated
group was not observed, within the experimental period
(5 days), whereas other studies (King et al., 2008; Xiao et al.,
2014) showed that normoglycemia (blood glucose
<13.8 mmol/l) was achieved after 5 days. Furthermore, the
return of hyperglycemic state following removal of graft
suggested the functionality of APT070-treated islet in vivo
(Supplementary Figure S3).
Given that the majority of the membrane-localizing com-
plement regulator was internalized by 40 h after intragraft de-
livery of APT070 (Patel et al., 2006), the stability of APT070 in
islets is a major obstacle that remains to be overcome. This
may explain why the inhibitory action of APT070 on IFN-γ
production was lost after 9 days of transplantation (Figure 7).
Ideally, APT070 should persist and control complement
activation indeﬁnitely (Patel et al., 2006). Consequently, the
possibility that combination therapy with APT070 can
contribute to the permanent survival of human islet grafts is
being explored.
In conclusion, this study demonstrates that APT070
prevented early islet damage involved in membrane leakage,
activation of complement and deposition of the membrane
attack complex in vitro and in vivo. Although the beneﬁt did
not translate into a statistically signiﬁcant improvement of
human islet allograft survival, the fact that both cytokine
levels and tissue damage were considerably improved indi-
cates the importance of APT070 as a potential therapeutic
tool. These data might provide a rationale for considering
clinical trials of APT070 in human islet transplantation, and
other complement dependent disorders.
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Figure 1 Assessment of APT070-treated islet viability. Hu-
man islets were treated with APT070 of serial dilutions of
0.4 μM to 0.16 μM, and then stained with ﬂuorescein
diacetate (green) and propidium iodide (red). Control islets
received no treatment. Inset images show enlarged area indi-
cated by a white arrow. Green and red colours indicate live
and dead cells respectively.
Figure 2 Flow cytometry analysis of human cell grafts three
months after CD34+ stem cell reconstitution in NSG mice.
Each plot represents one mouse. (A) The percentage of hu-
man cell engraftment in the peripheral blood 16 weeks after
CD34+ stem cell injection. (B) Representative plot of ﬂow cy-
tometry analysis.
Figure 3 Non-fasted plasma glucose level over time in
islet transplanted NSG mice rendered diabetic with
streptozotocin. Values are shown as means ± SD. N = 3 ani-
mals for each group. Nephrectomy: graft-bearing kidney was
removed. Normoglycemia was deﬁned as ≤ 3.8 mM glucose
in plasma.
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